FDA approves BMS’ oral formulation of existing acute leukemia drug in continuation therapy setting
BMS received approval for Onureg in the continuation setting of acute myeloid leukemia. The drug uses the same pharmaceutical molecule as Vidaza, a drug given via IV or subcutaneously that is used upfront, but it is not intended as a substitute for it.
